Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03937999 · ClinicalTrials.gov registry record · Phase 4
Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.
A Phase 4 study, sponsored by Montefiore Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03937999 is a Phase 4 study that was terminated before completion, run by Montefiore Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT03937999, a Phase 4 study, was terminated before completion, sponsored by Montefiore Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will examine whether the human monoclonal antibody, bezlotoxumab administered AFTER acute Clostridioides difficile (C.diff) has resolved, but during a period of subsequent antibiotic therapy, will eliminate the high risk of C. diff relapse.
Interventions
- DRUG Bezlotoxumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-08-30 |
| Est. Completion | 2022-05-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03937999
The ClinicalTrials.gov registry entry for NCT03937999 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bezlotoxumab is the first listed.
NCT03937999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03937999 about?
NCT03937999 is a clinical study titled "Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.". This study will examine whether the human monoclonal antibody, bezlotoxumab administered AFTER acute Clostridioides difficile (C.diff) has resolved, but during a period of subsequent antibiotic therapy, will eliminate the high risk of C. diff relapse.
What is the current status of trial NCT03937999?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2019-08-30. Estimated completion is 2022-05-15.
What interventions are being tested in trial NCT03937999?
The interventions under investigation include: Bezlotoxumab (DRUG).
Who is sponsoring clinical trial NCT03937999?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.